Should NICE’s threshold range for cost per QALY be raised? No

doi:10.1136/bmj.b185

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ comment articles:

From

Limit by

Our online table of contents is updated at least twice each day. Read all articles published in the last 7 days.
Keep up to date with cardiology: Access the latest cardiovascular medicine resources from across BMJ Group.
The BMJ iPad app brings you the best of print and online, including live links to the latest news, blogs, video, and podcasts. Get the BMJ iPad app.
OPEN ACCESS: All research articles are freely available online, with no word limit. Find out more about the BMJ's open access policy. Submit your paper.
Countdown to London 2012: BMJ Group's Olympics portal highlights latest Olympics and sports medicine-themed research, comment and learning

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

James Raftery, professor of health technology assessment

¹University of Southampton, Southampton SO16 7PX

raftery{at}soton.ac.uk

NICE has recently raised the threshold for end of life drugs. Adrian Towse (doi:10.1136/bmj.b181) argues it should consider doing the same for other treatments, but James Raftery believes that the threshold is already too high

The fact that the National Institute for Health and Clinical Excellence (NICE) has not updated its cost effectiveness threshold over the past decade means that the threshold has been falling. This applies whether adjusted for inflation (up 40% from 1999 to 2007) or for the NHS budget (up 90%).1 This decline is appropriate for several reasons. The correct threshold value, which should be set by the value of those technologies displaced by NICE guidance, seems to be lower. NICE has recently increased the threshold for end of life treatments. To offset this, the general threshold should be reduced. Precedent in the form of treatments previously funded has arguably influenced what people think the threshold should be. The most plausible precedent thresholds are no higher than those of NICE.